| CEO Name | Michael Amoroso |
| Nationality | United States |
| Net Worth Estimation | $5 million |
Michael Amoroso's estimated net worth of around $5 million derives primarily from his executive compensation, stock options, and equity holdings in Precision BioSciences (NASDAQ: DTIL), alongside prior leadership roles in other biotech firms. Factors such as recent SEC filings, salary disclosures, and the company's fluctuating market capitalization influence this valuation.
Michael Amoroso, CEO of Precision BioSciences, has an estimated net worth of $5,000,000, which is 5% of the industry's maximum CEO net worth and 50% of the minimum benchmark. His net worth is significantly below the biotechnology sector's typical CEO range of $10,000,000 to $80,000,000.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Michael Amoroso Performance in Precision BioSciences
Michael Amoroso, CEO of Precision BioSciences, demonstrates strategic leadership by driving innovation in gene editing technologies. His decisive actions in securing partnerships and advancing therapeutic pipelines have accelerated company growth and market presence. Under Amoroso's leadership, Precision BioSciences has enhanced operational performance and strengthened its position in the biotech industry.
Latest News
Precision BioSciences CEO Michael Amoroso Sells Shares Worth Over $24,600 as Company Advances Gene Editing Pipeline
Precision BioSciences announced that CEO Michael Amoroso recently sold 3,012 shares valued at $24,668, as the company highlighted progress in its gene-editing therapies, including upcoming clinical data for its ARCUS platform. The company also reported a Q3 2025 loss of $21.8 million and reaffirmed its focus on advancing treatments for hepatitis B and Duchenne muscular dystrophy.
Source: http://www.investing.com/news/insider-trading-news/precision-biosciences-ceo-michael-amoroso-sells-shares-worth-24668-93CH-3703974